Search PubMed⌕ Search

Biomedical subjects

P Nicolas

Publications and source records attributed to P Nicolas.

At least 145 records · Page 8Linked to original sources
PubMed1989

Properties and nucleotide sequence of a mitochondrial plasmid from sunflower.

The 1.413 circular supercoiled mitochondrial DNA plasmid P1 from a fertile sunflower line was sequenced, and a series of 160 bp tandemly repeated sequences was observed. The P1 plasmid was detected in both fertile and cytoplasmic male-sterile (CMS) lines, but in different quantities. Two other circular plasmids, P2 and P3, each 1.8 kbp in length, were shown to share common sequences with P1. The mitochondrial plasmid P1 detected homologous sequences in the nuclear DNA of sunflower, but not in chloroplast DNA nor in main band mitochondrial DNA. RNA molecules of about 680 and 550 nucleotides were detected that were complementary to mt plasmid P1.

Base Sequence↗
PubMed1989

Evidence for the synthesis of pro-CRF (corticotropin-releasing factor) in cultured fetal pancreatic islets of rats.

Immunoreactive species extracted from cultured pancreatic fetal islets of rat have been immunoprecipitated with anti-CRF (corticotropin-releasing factor) antibody and labeled with 125I. This material was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis. These immunoreactive species corresponded to CRF-like material detected by immunocytochemistry in certain cells of the islets of Langerhans. The analysis of immunoprecipitated material showed that it contained an immunoreactive polypeptide chain of 17,000. This band corresponds to the precursor minus the signal peptide as deduced by cDNA cloning analysis. A lower molecular weight immunoreactive material was also detected, apparently derived from the precursor by peptide bond cleavage which yielded intermediate fragments. These bands disappeared and generated a Mr 4000 when the corresponding species, fractionated by Sephadex G-25 column, were incubated with isolated islet extracts at pH 5.5. In isolated islets from 3-day-old rat, only the Mr 17,000 and 4000 species appeared. These results suggest strongly that CRF is synthesized in situ and that the conversion process could involve a sequential rather than a single cleavage of pro-CRF. The major end product was probably CRF, whereas intermediate forms seem to carry an NH2 terminal extension of CRF.

Animals↗
PubMed1989

Spatial filtering in multichannel magnetoencephalography.

Partial differential equations in boundary-value problems have been studied in order to estimate the influence of several geometrical and physical parameters involved in the outward transmission of the brain's magnetic field. Explicit Green kernels are used to obtain integral forms of generalized solutions which can be deduced from each other, as expressed over concentric spherical surfaces. That leads to numerical applications dealing with the radial component of the magnetic field. From this study, a new spatial filtering is proposed as a possible improvement in two-dimensional magnetoencephalographic mapping using large multisensors.

Electromagnetic Fields↗
PubMed1989

Dermorphin and related peptides in rat tissues.

Dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2), a naturally occurring peptide isolated from arboreal frog skin, is endowed with outstanding structural and biological features. It has no structural community with the sequence of mammalian opioid peptides and is a unique example of a D-aminoacid containing peptide which is synthesized via ribosomal route. Dermorphin is the most potent of the opioid peptides or opiates in producing long lasting analgesia and catalepsy. Since most amphibians' secretory peptides have counterparts in the mammalian central nervous system and gastrointestinal tract, we have developed a sensitive enzyme immunoassay that can detect 1 pg dermorphin to verify the possibility of dermorphin or dermorphin-related peptides occurrence in mammalian tissues. Dermorphin-related peptides were purified by fast protein liquid chromatography followed by reverse phase high pressure liquid chromatography. Identification was achieved by chromatographic comparison with synthetic standards and immunological analysis. A peptide behaving like authentic dermorphin was detected (2 ng/g) in rat small intestine. Immunoreactive species of higher Mr were also detected in the brain, adrenal glands and gastrointestinal tract, they may represent extended forms of dermorphin or homologous peptides.

Animals↗
PubMed1989

Central-type benzodiazepines and the octadecaneuropeptide modulate the effects of GABA on the release of alpha-melanocyte-stimulating hormone from frog neurointermediate lobe in vitro.

The involvement of the GABA-benzodiazepine receptor complex in the regulation of melanotropin secretion has been investigated using perfused frog neurointermediate lobes. The GABAA agonist 3-amino-1 propane sulfonic acid mimicked the biphasic effect of GABA on alpha-melanocyte-stimulating hormone secretion: a brief stimulation followed by an inhibition of melanotropin secretion. The GABAA antagonist SR 95531 (10(-4) M) inhibited both stimulation and inhibition of alpha-melanocyte-stimulating hormone release induced by GABA (10(-4) M). Since the inhibitory effect of baclofen (10(-4) M) was partially antagonized by SR 95531 (10(-4) M), it appears that the GABAergic control of alpha-melanocyte-stimulating hormone release is mainly achieved through activation of GABAA receptors. GABA-induced stimulation of alpha-melanocyte-stimulating hormone release was inhibited by tetrodotoxin (10(-5) M), an Na+ -channel blocker, or nifedipine (10(-5) M), a voltage-dependent Ca2+ -channel blocker, suggesting that Na+ and Ca2+ ions are involved in the stimulatory phase of GABA action. Only central-type benzodiazepine binding site agonists such as clonazepam (10(-4) M) modified alpha-melanocyte-stimulating hormone release. In fact, clonazepam (10(-7) to 10(-5) M) led to a dose-dependent potentiation of both GABA-induced stimulation and inhibition of alpha-melanocyte-stimulating hormone release. This potentiating effect was antagonized by the GABAA antagonist SR 95531 (10(-4) M) or by the central-type benzodiazepine binding site antagonist flumazenil (10(-4) M), whereas picrotoxin (10(-4) M) abolished only the stimulatory phase.(ABSTRACT TRUNCATED AT 250 WORDS)

Animals↗
PubMed1989

Effect of nifedipine on thyrotropin, prolactin, and thyroid hormone release in man: a placebo-controlled study.

Nifedipine (10 mg tid) or placebo was administered in a randomized double-blind trial for 1 wk to 2 groups of 10 mildly hypertensive euthyroid patients. Hormonal concentrations (thyrotropin [TSH], prolactin [PRL], thyroxin, triiodothyronine, and reverse triiodothyronine) before and during a TRH test were assessed in the 2 groups before (D0) and after (D7) each treatment. Parameters of the TRH test were determined (peak values, area under the curve [AUC], release [Kr], and elimination [Ke] rate constants) and their D7:D0 ratios were compared in the 2 groups. The TSH (peak values and Kr) and PRL (peak values and AUC) responses to TRH were significantly decreased in the nifedipine group compared to the placebo group. Neither basal nor TRH-stimulated thyroid hormone levels were modified. These results confirm experimental data but seem to be clinically irrelevant.

Adult↗
PubMed1989

Thyroid hormone regulation of neurons staining for a pro-TRH-derived cryptic peptide sequence in the rat hypothalamic paraventricular nucleus.

The influence of thyroid hormones on neurons staining for a pro-TRH-derived cryptic peptide sequence in the rat hypothalamic paraventricular nucleus was assessed by using quantitative immunocytochemistry. The antiserum used for immunocytochemical studies recognized a cryptic fragment of pro-TRH located in the Phe 178-Ser 186 region of the precursor. Hypothyroid female rats obtained following 1 month administration of 6-n-propyl-2-thiouracil (PTU) as well as euthyroid animals were treated with a low (3 micrograms/kg/day) or high (67 micrograms/kg/day) dose of L-thyroxine (T4) for 4-10 days before sacrifice. All the animals received an intraventricular injection of colchicine 2 days prior to perfusion with 4% paraformaldehyde. PTU treatment induced an increase (45% over control) in the number of immunostained neurons. The administration of a low dose of T4 to hypothyroid animals slightly increased the number of staining for a pro-TRH-derived cryptic sequence neurons, while being uneffective in euthyroid rats. In hypothyroid animals, a 4-day treatment with the high dose of T4 did not produce any changes whereas the 7-day treatment reduced the number of positive cells to 42% of control. In euthyroid rats treated with the high dose of T4 for 4 and 7 days, the number of stained neurons was reduced to 60 and 37% of control, respectively. These results indicate that thyroid hormones can modify the amounts of staining for a pro-TRH-derived cryptic sequence in hypothalamic paraventricular neurons.(ABSTRACT TRUNCATED AT 250 WORDS)

Amino Acid Sequence↗
PubMed1989

Processing of thyrotropin-releasing hormone prohormone (pro-TRH) in the adult rat pancreas: identification and localization of pro-TRH-related peptides in beta-cells of pancreatic islets.

Rat TRH prohormone (pro-TRH) contains five separate copies of the TRH progenitor sequence, Gln-His-Pro-Gly. All five sequences are flanked by paired basic amino acid cleavage sites and linked together by connecting sequences. RIAs to synthetic TRH and prepro-TRH-(178-199) were used to investigate pro-TRH processing in the endocrine pancreas of adult rats. HPLC analysis of adult rat pancreatic extracts showed the presence of a major immunoreactive peptide eluting at the position of prepro-TRH-(178-199). An additional peak coeluting with [less than Glu172]prepro-TRH-(172-199) (less than Glu = pyroglutamyl) revealed the presence of a C-terminally extended form of TRH. Quantification of TRH in pancreatic extracts indicated the presence of 22 mol TRH/mol prepro-TRH-(178-199) and 17 mol TRH/mol [less than Glu172]prepro-TRH-(172-199). Treatment of rats with streptozotocin markedly reduced the pancreatic content of both immunoreactive TRH (-84%) and immunoreactive prepro-TRH-(178-199) (-62%). Light microscopic immunocytochemistry showed that prepro-TRH-(178-199)-like immunoreactivity was exclusively located within insulin-containing cells of the pancreatic islets. At the electron microscopic level, prepro-TRH-(178-199) immunoreactivity appeared to be concentrated in secretory granules. The present study demonstrates that processing of pro-TRH generates both non-TRH- and TRH-related peptides in the adult rat pancreas. Our data also indicate that beta-cells of the endocrine pancreas are the major source of TRH- and pro-TRH-derived peptides.

Amino Acid Sequence↗
PubMed1989

Dermenkephalin (Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2): a potent and fully specific agonist for the delta opioid receptor.

Dermorphin, Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2 is an extraordinarily potent and highly mu-selective opioid heptapeptide isolated from amphibian skin. It is unique among peptides synthesized by animal cells in having an amino acid residue in the D-configuration. At least two different preprodermorphin cDNAs were cloned from skin of Phylomedusa sauvagei; their predicted amino acid sequences contained four to five homologous repeats of 35 amino acids, each repeat including one copy of the dermorphin progenitor sequence. Tyr-Ala-Phe-Gly-Tyr-Pro-Ser-Gly, flanked by Lys-Arg at the amino end and by Glu-Ala-Lys-Lys at the carboxyl end [Science (Wash. D. C.) 238:200-202 (1987)]. The D-Ala in position 2 in dermorphin is encoded by a usual Ala codon in the precursor sequence. Of the two prodermorphin molecules, one has a dermorphin copy replaced with a distinct heptapeptide same processing signals. Assuming the same pathway as for the release of dermorphin, processing of this precursor may yield, beside dermorphin, a copy of a new peptide, Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2. We have synthetized this peptide together with its (L-Met2)-counterpart and evaluated their respective opioid receptor selectivity in the mouse vas deferens and guinea pig ileum assays and in rat brain membrane binding assays. Overall, the data collected demonstrate that the putative prodermorphin product Tyr-D-Met-Phe-His-Leu-Met-Asp-NH2 named dermenkephalin, behaves as a potent delta opioid agonist exhibiting high affinity and high selectivity for the delta opioid receptor. Prodermorphin, thus, offers a surprising example of an opioid biosynthetic precursor that might simultaneously generate highly potent and fully selective agonists for the mu- (morphine) and the delta (enkephalin) opioid receptors, respectively. In addition, because dermenkephalin has no structural features in common with the sequence of all the hitherto known opioid peptides, it should be a useful tool for identifying conformational determinants for high affinity and selective binding of opioids to the delta receptor.

Amino Acid Sequence↗
PubMed1988

Processing of thyrotropin-releasing hormone prohormone (pro-TRH) generates pro-TRH-connecting peptides. Identification and characterization of prepro-TRH-(160-169) and prepro-TRH-(178-199) in the rat nervous system.

Rat thyrotropin-releasing hormone prohormone (pro-TRH) contains five separate copies of the TRH progenitor sequence: Gln-His-Pro-Gly. Each of the five sequences is flanked by pairs of basic residues and linked together by one of several predicted connecting sequences. Two of the pro-TRH-connecting peptides, prepro-TRH-(160-169) and prepro-TRH-(178-199), were detected in extracts of rat neural tissues by radioimmunoassay using antibodies directed against the corresponding synthetic probes. Endogenous prepro-TRH-(160-169) and prepro-TRH-(178-199) were purified by gel exclusion chromatography, reverse-phase high pressure liquid chromatography, and ion-exchange chromatography. Structural identification of each peptide was achieved by chromatographic comparison with synthetic standards, immunological analysis, and tryptic mapping. Equimolar amounts of these connecting fragments were observed in hypothalamus and spinal cord. Quantification of TRH in spinal cord and hypothalamus extracts revealed the presence of 4.9-6.3 mol of TRH/mol of prepro-TRH-(178-199) and 4.4-6 mol of TRH/mol of prepro-TRH-(160-169), respectively. By using the indirect immunofluorescence technique, prepro-TRH-(178-199) immunoreactive cell bodies were found in the paraventricular nucleus of the hypothalamus, and a dense plexus of immunopositive nerve terminals was observed in the external zone of the median eminence, in a distribution similar to that described for TRH. These studies demonstrate that prepro-TRH-(160-169) and prepro-TRH-(178-199) are, together with TRH, predominant storage forms of the TRH precursor in hypothalamus and spinal cord, being present in molar ratios corresponding to those expected for a nearly complete processing of the prohormone molecule. The presence of pro-TRH-connecting peptides in various brain regions, including the median eminence, suggests that these peptides might act as neuromodulators in the central nervous system and/or neuroendocrine signals at the pituitary level. In the olfactory lobes, prepro-TRH is processed differently since a C-terminally extended form of TRH, prepro-TRH-(172-199), is found as a major end product along with lower but significant amounts of prepro-TRH-(178-199) and prepro-TRH-(160-169). The striking difference in pro-TRH processing patterns among the various tissues examined suggests differential regulating mechanisms for TRH and/or TRH-related activities.

Amino Acid Sequence↗
PubMed1988

Effective high-performance liquid chromatographic determination of glafenine in plasma: pharmacokinetic application.

A high-performance liquid chromatographic method for an effective determination of glafenine and its main metabolite, glafenic acid, is described. The assay involves separate extraction procedures for glafenine and for its metabolite, but the same internal standard (floctafenine) and the same chromatographic conditions (including a 5-micron C8 column, a quaternary solvent mixture of water-acetonitrile-diethylamine-acetic acid and an ultraviolet detector set at 360 nm). For 1 ml of plasma, the detection limit is 0.05 mg/l for glafenine and 0.25 mg/l for glafenic acid. Compared with previously described techniques, this assay uses a very low glafenine linearity range, which allows the true pharmacokinetics of this drug to be described for the first time.

Chromatography, High Pressure Liquid↗
PubMed1988

Immunocytochemical distribution of neurons containing a peptide derived from thyrotropin-releasing hormone precursor in the rat brain.

Using an antiserum to a 22-amino acid synthetic peptide corresponding to sequence 178-199 of the precursor of thyrotropin-releasing hormone (pro-TRH), we have studied by immunocytochemistry the distribution of immunoreactive pro-TRH in the rat brain. Immunostaining found in several regions of the brain had a distribution similar to that previously reported for TRH. Reaction product was found in both neuronal cell bodies and processes. These results indicate that peptide(s) derived from pro-TRH are transported along the axons with TRH itself. Moreover, the presence of immunoreactive nerve endings in different areas including the median eminence suggests that this material might have a neuromodulator/neurotransmitter role in the central nervous system and could also be released into the pituitary portal plexus.

Animals↗
PubMed1988

Secondary processing of neurohormones: intracellular proteolytic cleavage of beta-endorphin generates new active neuropeptides.

The following short review considers the physiological significance of naturally occurring peptide fragments derived from intracellular secondary processing of beta-endorphin (beta-EP). Particular attention will be given to the question of whether truncated and/or derivatized forms of beta-EP are true end products subject to release and regulation and might serve important new functions. Since collectively endorphins may play a variety of neurobiological roles which may or may not be mediated through analgesic receptors, most of the material reviewed herein deals with the induction of analgesia, the most commonly used measure of the opiate's acute effects.

Amino Acid Sequence↗
PubMed1988

Structural requirements for dermorphin opioid receptor binding.

Structural features influencing binding activity of dermorphin to opioid receptors have been investigated in the rat brain through the synthesis and evaluation of binding affinity of a series of synthetic dermorphin analogs. Tritiated dermorphin was used as primary ligand. The single population of high affinity dermorphin binding sites present in the rat brain is clearly of an opioid nature since bound radiolabeled dermorphin was fully displaced with high affinity either by morphine or naloxone. Displacement of tritiated dermorphin by all alkaloid opiates or dermorphin related peptides tested was monophasic, consistent with simple competitive inhibition at a single population of binding sites. Dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) was the most potent competitor in all experiments. The D-configuration of the amino acid residue in position 2 was found to be of crucial importance for binding. Replacement of D-Ala2 with L-Ala led to a deleterious effect, this analog being 1/5000th as potent as dermorphin in displacing bound tritiated dermorphin from its receptor. Shorter dermorphin homologs, dermorphin-(1-4)-NH2 and dermorphin-(1-3)-NH2, were found to be 20 and 40-fold less potent, respectively, than dermorphin. The C-terminal carboxamide function is of significant importance for manifestation of the full intrinsic binding potency of dermorphin. Deamidated dermorphin had 1/5th the potency of the parent peptide. This suggests that while the whole dermorphin sequence is required for the expression of the full intrinsic binding activity of the molecule, the N-terminal tripeptide is a key structure as it contains the features which allow receptor recognition.

Analgesics, Opioid↗
PubMed1988

Characterization of the receptor binding profile of (3H)-dermorphin in the rat brain.

Amphibian skin synthesizes a variety of biologically active peptides. Of these, dermorphin (Tyr-D-Ala-Phe-Gly-Tyr-Pro-Ser-NH2) is an extraordinarily potent opioid peptide up to 1000 times more active than morphine in inducing analgesia after intracerebroventricular administration. Dermorphin has little in common with the sequence of all hitherto known mammalian opioid peptides and is unique in having a D-amino acid residue in position 2. Specific binding properties of tritium labeled dermorphin were characterized in the rat brain. Scatchard or Hill analysis of equilibrium measurements performed over a large range of concentrations revealed a single population of dermorphin binding sites with a Kd value of 0.46 nM. Dermorphin and the selective mu-receptor ligand (D-Ala2, MePhe4, Gly5-ol)-enkephalin (DAGO) had similar high potencies in competing with (3H)-dermorphin binding, whereas the inverse holds for the prototypical delta receptor ligand (D-Pen2, D-Pen5)-enkephalin (DPDPE), which exhibited a potency three orders of magnitude lower. Dermorphin was tested for its relative affinity to mu and delta binding sites by determining its potency in displacing (3H)-DAGO and (3H)-DPDPE from rat brain membrane preparations. Based on these comparisons, dermorphin exhibited a selectivity ratio Ki(DPDPE)/Ki(DAGO) = 100, a value almost identical to that of DAGO, this ligand being considered as the protypical mu-receptor probe. The high affinity and selectivity of (3H)-dermorphin together with its very low nonspecific binding make this peptide a useful tool for dissecting the role(s) of the mu-receptor(s).

Analgesics, Opioid↗
PubMed1987

Specific opioid binding sites for dermorphin in rat brain. A radioreceptor assay using the tritiated hormone as primary ligand.

Dermorphin, a heptapeptide amide isolated from amphibian skin, is the most potent of the naturally occurring opioid peptides. (3H)-dermorphin (52 Ci/mmol, 1294 GBq/mmol) was prepared by catalytic tritiation of the synthetic (2,5-iodotyrosyl 1,5)-dermorphin precursor. High affinity specific binding sites for dermorphin were labeled in rat brain membranes using tritiated dermorphin as primary ligand. The binding was saturable and time-dependent. Scatchard analysis revealed a single population of non-interacting high affinity sites (Kd = 0.86 nM). Dermorphin and the specific opiate antagonist naloxone inhibited specific (3H)-dermorphin binding in a concentration dependent manner. The displacement curves could be fit to a simple competitive model assuming only one population of binding sites, with IC 50 of 1.6 nM and 3.4 nM for dermorphin and naloxone, respectively. The use of tritiated dermorphin will be helpful to ascertain unequivocally the selectivity of dermorphin for the different opioid receptor subtypes in the central nervous system.

Animals↗